Search This Blog

Monday, May 4, 2026

Rhythm Pharma new long-term, Phase 3 pediatric IMCIVREE data in acquired hypothalamic obesity

 

Rhythm Pharma reports new long-term and Phase 3 pediatric IMCIVREE data showing sustained BMI and weight-category improvements in acquired hypothalamic obesity

  • Data presented at Pediatric Endocrine Society meeting highlight durable BMI reductions and improved weight categories with setmelanotide.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)